Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production

Agriculture & Biology

• lymphocyte antigens 100%
• cytotoxic T-lymphocytes 92%
• cytokines 62%
• T-lymphocytes 60%
• neoplasms 50%
• melanoma 25%
• vaccines 18%
• receptors 18%
• lectins 15%
• antibodies 10%
• immune response 9%
• therapeutics 8%
• autoimmunity 7%
• immunotherapy 7%
• lymph nodes 5%
• cells 5%
• ligands 4%
• cell proliferation 4%
• monitoring 3%
• mice 3%
• methodology 1%

Medicine & Life Sciences

• CTLA-4 Antigen 91%
• Cell Proliferation 43%
• Cytokines 40%
• T-Lymphocytes 40%
• NK Cell Lectin-Like Receptors 32%
• Experimental Melanomas 22%
• Neoplasms 21%
• Vaccines 13%
• Tumor Necrosis Factor Receptor Superfamily, Member 9 11%
• Antibodies 9%
• flt3 ligand protein 8%
• Cancer Vaccines 7%
• Regulatory T-Lymphocytes 5%
• Autoimmunity 5%
• Immunotherapy 5%
• Melanoma 4%
• Lymph Nodes 4%
• Therapeutics 2%

Chemistry

• Antigen 55%
• Effector 41%
• Marker 8%